Performance analysis of Revance Therapeutics (RVNC)
Annual Return
Over the past 3 years, RVNC has had an average annual return of -51.06%, underperforming the benchmark SPY, which returned +22.45% annual.
Over the past 5 years, RVNC has had an average annual return of -33.49%, underperforming the benchmark SPY, which returned +13.88% annual.
Over the past 10 years, RVNC has had an average annual return of -15.26%, underperforming the benchmark SPY, which returned +15.44% annual.
Since Feb 6, 2014, RVNC has had an average annual return of -14.95%, underperforming the benchmark SPY, which returned +14.37% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +0% | +20.05% | -65.42% | -52.38% | +13.11% | -42.42% | +74.61% | -19.37% | -43.70% | +72.72% | -39.41% | +101.66% |
| 2014 | |||||||||||
| -36.91% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0% | +0% | +0% | +0% | +0% | +0% | |||||||
| 2025 | +19.43% | +0.52% | +20.05% | ||||||||||
| 2024 | -42.79% | +41.96% | -31.10% | -26.58% | -21.34% | -9.55% | +47.13% | +73.79% | -21.01% | +13.66% | -38.78% | -15.84% | -65.42% |
| 2023 | +87.87% | +0.06% | -7.18% | -1.18% | -3.99% | -17.19% | -6.63% | -25.39% | -34.94% | -31.20% | -14.22% | +29.87% | -52.38% |
| 2022 | -18.31% | +1.79% | +43.71% | -16.00% | -16.49% | +1.02% | +12.30% | +28.24% | +35.67% | -17.37% | -2.68% | -14.98% | +13.11% |
| 2021 | -10.23% | +3.22% | +6.44% | +4.18% | +1.69% | +0.10% | -1.88% | -7.91% | +4.03% | -50.65% | -0.51% | +19.29% | -42.42% |
| 2020 | +37.82% | +3.36% | -35.99% | +25.07% | +12.91% | +16.84% | -3.85% | +24.48% | -13.99% | +2.95% | -6.72% | +17.40% | +74.61% |
| 2019 | -14.21% | -1.91% | -6.96% | -16.00% | -18.66% | +20.44% | -3.02% | -15.73% | +22.64% | +20.45% | +14.32% | -9.33% | -19.37% |
| 2018 | -9.65% | -4.18% | -0.49% | -9.25% | -0.18% | -1.62% | +4.74% | -4.70% | -9.31% | -12.39% | -6.11% | -1.52% | -43.70% |
| 2017 | -3.37% | +4.99% | -0.95% | +4.57% | +2.30% | +18.64% | -13.82% | +7.91% | +12.23% | -5.63% | +6.73% | +28.83% | +72.72% |
Drawdown analysis of Revance Therapeutics (RVNC)
The maximum drawdown for the RVNC was -94.26%, occurring on Jun 26, 2024. This drawdown has not yet recovered.
The current RVNC drawdown is -91.05%.
Since Feb 6, 2014 RVNC has experienced the following drawdowns:
- 50% or more: 2 times
- 40% or more: 2 times
- 30% or more: 2 times
- 20% or more: 2 times
- 10% or more: 4 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -94.26% | Nov 11, 2015 | 2168 | Jun 26, 2024 | Ongoing | Ongoing | Ongoing |
| -61.72% | Mar 12, 2014 | 145 | Oct 7, 2014 | 269 | Oct 30, 2015 | 414 |
| -10.61% | Nov 2, 2015 | 3 | Nov 5, 2015 | 4 | Nov 11, 2015 | 7 |
| -10.53% | Feb 25, 2014 | 3 | Feb 28, 2014 | 3 | Mar 5, 2014 | 6 |
| -7.50% | Feb 7, 2014 | 8 | Feb 20, 2014 | 1 | Feb 21, 2014 | 9 |
| -0.87% | Feb 21, 2014 | 1 | Feb 24, 2014 | 1 | Feb 25, 2014 | 2 |